Renal Cell Carcinoma

Latest News


Video Series


Latest Videos


Shorts

Initial Assessments in Metastatic RCC
0:38
Initial Assessments in Metastatic RCC
8 months ago
by
David Braun, MD, PhD

CME Content


More News

The CYTOSHRINK trial showed that incorporating stereotactic body radiation therapy (SBRT) with ipilimumab and nivolumab did not enhance progression-free survival and resulted in a shorter median PFS compared to immunotherapy alone for advanced renal cell carcinoma.